Table 2.
Baseline characteristics (treated set; n = 7034)
| Age (years), mean (SD) |
63.1 (8.6) |
| ≥ 75 years of age, n (%) |
652 (9) |
| Male, n (%) |
5026 (72) |
| Race, n (%) |
|
| White |
5089 (72) |
| Asian |
1518 (22) |
| Black/African American |
357 (5) |
| Other* |
70 (1) |
| Ethnicity, n (%) |
|
| Hispanic or Latino |
1268 (18) |
| Smoking history, n (%) Current/Ex-smoker |
930 (13)/3216 (46) |
| Time since diagnosis, n (%) |
|
| ≤5 years |
1265 (18) |
| >5-10 years |
1754 (25) |
| >10 years |
4015 (57) |
| Region, n (%) |
|
| Europe |
2885 (41) |
| North America/Australia/New Zealand |
1408 (20) |
| Latin America |
1081 (15) |
| Africa |
313 (4) |
| Asia |
1347 (19) |
| Northeast Asia |
586 (8) |
| South/South-East Asia |
761 (11) |
| CV risk factors, any of the below, n (%) |
6978 (99) |
| History of MI |
3275 (47) |
| Single-vessel CAD |
743 (11) |
| Multi-vessel CAD |
3285(47) |
| CABG |
1738(25) |
| History of stroke |
1631 (23) |
| Peripheral occlusive arterial disease |
1449 (21) |
| Glucose-lowering therapy at baseline, n (%) |
|
| None |
128 (2) |
| Monotherapy |
2055 (29) |
| Metformin (% of monotherapy) |
745 (36) |
| Insulin (% of monotherapy) |
954 (46) |
| Dual therapy |
3188 (45) |
| Metformin + sulfonylurea (% of dual therapy) |
1383 (43) |
| Metformin + insulin (% of dual therapy) |
1420 (45) |
| Other therapies (n, %) |
|
| Acetylsalicylic acid |
5990 (85) |
| Statins |
5387 (77) |
| Fibrates |
630 (9) |
| Any antihypertensive therapy (n, %) |
6641 (94) |
| Blockers of the renin-angiotensin system |
5651 (80) |
| Beta-blockers |
4537 (64) |
| Calcium channel blockers | 2114 (30) |
*American Indian/Native Alaskan/Native Hawaiian/Pacific Islander/missing.
Results (based on a pre-final version of the database of this ongoing trial) may change slightly once trial is completed.